Granules India

Granules India delivered a strong Q4 FY26 with revenue of ₹1,476 croreCurrent reported value: ₹1,476 crore. No comparable prior figure is available in the source record. (+23Current reported value: 23. No comparable prior figure is available in the source record.% YoY), EBITDA of ₹352 croreCurrent reported value: ₹352 crore. No comparable prior figure is available in the source record. (+40% YoY), and PAT of ₹202 croreCurrent reported value: ₹202 crore. No comparable prior figure is available in the source record. (+33Current reported value: 33. No comparable prior figure is available in the source record.% YoY). Gross margin expanded 233bps YoY to 65.7%, driven by a favorable mix shift toward complex generics and the peptide CDMO business, which turned EBITDA-positive for the first time. Full-year revenue crossed ₹5,000 croreCurrent reported value: ₹5,000 crore. No comparable prior figure is available in the source record. for the first time, growing 20% YoY. Europe revenue surged 81% YoY, now 15% of total. The Gagilapur remediation is substantially complete, with the company awaiting FDA reinspection. Guidance for FY27 includes sustained USFDA readiness, scaling of peptide CDMO, and capex of ~₹600 crore. Key risk: prolonged uncertainty in raw material and freight costs due to geopolitical tensions, which could pressure margins if price increases lag.